Frontline gefitinib in advanced non-small cell lung cancer: Meta-analysis of published randomized trials
<b>Objective</b> : Gefitinib, a small molecule tyrosine kinase inhibitor, showed a substantial effect as a salvage treatment for patients with advanced non-small cell lung cancer (NSCLC) who had failed prior chemotherapy. Subsequent phase III trials in previously untreated patients have...
Main Author: | |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2010-01-01
|
Series: | Annals of Thoracic Medicine |
Subjects: | |
Online Access: | http://www.thoracicmedicine.org/article.asp?issn=1817-1737;year=2010;volume=5;issue=3;spage=153;epage=160;aulast=Ibrahim |